Abstract
A remarkable proportion of factors causing genetic predisposition to breast cancer (BC) are unknown in non-BRCA1/2 families. Exome sequencing was performed for 13 high-risk Finnish hereditary breast and/or ovarian cancer (HBOC) families to detect variants contributing to BC susceptibility. After filtering, 18 candidate variants in DNA damage response (DDR) pathway genes were screened in 129 female HBOC patients, up to 989 female controls, and 31 breast tumours by Sanger sequencing/TaqMan assays. In addition, two variants were further studied in 49 male BC patients and 909 male controls. Second, all variants predicted to affect function in six early-onset BC patients were analysed in detail. Variants in ATM, MYC, PLAU, RAD1, and RRM2B were enriched in female HBOC patients compared with controls (odds ratio 1.16–2.16). A rare nonsynonymous variant in RAD50 was detected in a male BC patient. In addition, a very rare BRCA1 variant was identified in a single high-risk family. None of the variants showed wild-type allele loss in breast tumours. Furthermore, novel variants predicted to affect function were detected in early-onset patients in genes, which target DNA repair and replication, signalling, apoptosis, and cell cycle pathways. Family-specific enrichment of multiple DDR pathway gene defects likely explains BC predisposition in the studied families. These findings provide new information on potential BC-related pathways and an excellent premise for future studies.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ferlay J, Soerjomataram I, Dikshit R et al: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359–E386.
Claus EB, Schildkraut JM, Thompson WD, Risch NJ : The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77: 2318–2324.
Roy R, Chun J, Powell SN : BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 2011; 12: 68–78.
Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M : Genetic susceptibility to breast cancer. Mol Oncol 2010; 4: 174–191.
Antoniou A, Pharoah PD, Narod S et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117–1130.
Hartikainen JM, Kataja V, Pirskanen M et al: Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families. Clin Genet 2007; 72: 311–320.
Sarantaus L, Auranen A, Nevanlinna H : BRCA1 and BRCA2 mutations among Finnish ovarian carcinoma families. Int J Oncol 2001; 18: 831–835.
Michailidou K, Beesley J, Lindstrom S et al: Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet 2015; 47: 373–380.
Wen H, Kim YC, Snyder C et al: Family-specific, novel, deleterious germline variants provide a rich resource to identify genetic predispositions for BRCAx familial breast cancer. BMC Cancer 2014; 14: 470–2407-14-470.
Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL : Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res 2011; 13: R20.
Kuusisto KM, Akinrinade O, Vihinen M, Kankuri-Tammilehto M, Laasanen S, Schleutker J : Copy number variation analysis in familial BRCA1/2-negative Finnish breast and ovarian Cancer. PLoS One 2013; 8: e71802.
Purcell S, Neale B, Todd-Brown K et al: PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559–575.
Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR : ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003; 31: 3568–3571.
Forbes SA, Beare D, Gunasekaran P et al: COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015; 43: D805–D811.
Ahmed M, Rahman N : ATM and breast cancer susceptibility. Oncogene 2006; 25: 5906–5911.
Antoniou AC, Pharoah PD, McMullan G et al: A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002; 86: 76–83.
Heikkinen K, Rapakko K, Karppinen SM, Erkko H, Nieminen P, Winqvist R : Association of common ATM polymorphism with bilateral breast cancer. Int J Cancer 2005; 116: 69–72.
Thorstenson YR, Roxas A, Kroiss R et al: Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res 2003; 63: 3325–3333.
Hoffman B, Liebermann DA : Apoptotic signaling by c-MYC. Oncogene 2008; 27: 6462–6472.
Moquet-Torcy G, Tolza C, Piechaczyk M, Jariel-Encontre I : Transcriptional complexity and roles of Fra-1/AP-1 at the uPA/Plau locus in aggressive breast cancer. Nucleic Acids Res 2014; 42: 11011–11024.
Weigelt B, Geyer FC, Reis-Filho JS : Histological types of breast cancer: how special are they? Mol Oncol 2010; 4: 192–208.
Xu M, Bai L, Gong Y, Xie W, Hang H, Jiang T : Structure and functional implications of the human rad9-hus1-rad1 cell cycle checkpoint complex. J Biol Chem 2009; 284: 20457–20461.
Tanaka H, Arakawa H, Yamaguchi T et al: A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 2000; 404: 42–49.
Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61–70.
Xie L, Qin W, Li J et al: BNIPL-2 promotes the invasion and metastasis of human hepatocellular carcinoma cells. Oncol Rep 2007; 17: 605–610.
Wiesmann F, Veeck J, Galm O et al: Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer. Breast Cancer Res 2009; 11: R34.
Stone B, Schummer M, Paley PJ et al: MAGE-F1, a novel ubiquitously expressed member of the MAGE superfamily. Gene 2001; 267: 173–182.
Du Q, Zhang Y, Tian XX, Li Y, Fang WG : MAGE-D1 inhibits proliferation, migration and invasion of human breast cancer cells. Oncol Rep 2009; 22: 659–665.
Ali K, Mahjabeen I, Sabir M et al: Germline variations of apurinic/apyrimidinic endonuclease 1 (APEX1) detected in female breast cancer patients. Asian Pac J Cancer Prev 2014; 15: 7589–7595.
Laitinen VH, Rantapero T, Fischer D et al: Fine-mapping the 2q37 and 17q11.2-q22 loci for novel genes and sequence variants associated with a genetic predisposition to prostate cancer. Int J Cancer 2015; 136: 2316–2327.
Acknowledgements
We would like to thank all participating patients and their families. This work was supported by the Finnish Cancer Organisations, the Sigrid Juselius Foundation, and the Academy of Finland (251074) for JS. The Finnish Doctoral Programme in Biomedicine and Biotechnology, the Orion-Farmos Research Foundation, the Emil Aaltonen Foundation, the Ida Montini Foundation, and the Finnish Cancer Organisations have supported KM.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on European Journal of Human Genetics website
Supplementary information
Rights and permissions
About this article
Cite this article
Määttä, K., Rantapero, T., Lindström, A. et al. Whole-exome sequencing of Finnish hereditary breast cancer families. Eur J Hum Genet 25, 85–93 (2017). https://doi.org/10.1038/ejhg.2016.141
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ejhg.2016.141
This article is cited by
-
The association between ATM variants and risk of breast cancer: a systematic review and meta-analysis
BMC Cancer (2021)
-
Genetic Mutations Associated with Hormone-Positive Breast Cancer in a Small Cohort of Ethiopian Women
Annals of Biomedical Engineering (2021)
-
The impact of rare and low-frequency genetic variants in common disease
Genome Biology (2017)
-
Familial associations of male breast cancer with other cancers
Breast Cancer Research and Treatment (2017)
